Treatment for acquired aplasia and refractory cytopenia. Review of a historical cohort

array:24 ["pii" => "S2341287922001843" "issn" => "23412879" "doi" => "10.1016/j.anpede.2022.08.006" "estado" => "S300" "fechaPublicacion" => "2022-10-01" "aid" => "3284" "copyrightAnyo" => "2022" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "crp" "cita" => "An Pediatr (Barc). 2022;97:286-8" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "es" => array:20 [ "pii" => "S1695403322001394" "issn" => "16954033" "doi" => "10.1016/j.anpedi.2022.04.016" "estado" => "S300" "fechaPublicacion" => "2022-10-01" "aid" => "3284" "copyright" => "Asociación Española de Pediatría" "documento" => "simple-article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "crp" "cita" => "An Pediatr (Barc). 2022;97:286-8" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "es" => array:11 [ "idiomaDefecto" => true "cabecera" => "Carta científica" "titulo" => "Tratamiento de la aplasia adquirida y la citopenia refractaria. Revisión de una cohorte histórica" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "286" "paginaFinal" => "288" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Treatment for acquired aplasia and refractory cytopenia. Review of a historical cohort" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figura 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1224 "Ancho" => 2917 "Tamanyo" => 147510 ] ] "descripcion" => array:1 [ "es" => "A. Supervivencia libre de enfermedad de la cohorte tras primer tratamiento. B. Supervivencia global tras tratamiento inmunosupresor dependiendo del periodo entre diagnóstico y tratamiento." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Jesús González de Pablo, Cristina Jiménez Cobo, Daniel Azorín Cuadrillero, Marta González-Vicent, Julián Sevilla" "autores" => array:5 [ 0 => array:2 [ "nombre" => "Jesús" "apellidos" => "González de Pablo" ] 1 => array:2 [ "nombre" => "Cristina" "apellidos" => "Jiménez Cobo" ] 2 => array:2 [ "nombre" => "Daniel" "apellidos" => "Azorín Cuadrillero" ] 3 => array:2 [ "nombre" => "Marta" "apellidos" => "González-Vicent" ] 4 => array:2 [ "nombre" => "Julián" "apellidos" => "Sevilla" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2341287922001843" "doi" => "10.1016/j.anpede.2022.08.006" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2341287922001843?idApp=UINPBA00005H" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1695403322001394?idApp=UINPBA00005H" "url" => "/16954033/0000009700000004/v1_202210061345/S1695403322001394/v1_202210061345/es/main.assets" ] ] "itemSiguiente" => array:20 [ "pii" => "S2341287922001727" "issn" => "23412879" "doi" => "10.1016/j.anpede.2022.04.012" "estado" => "S300" "fechaPublicacion" => "2022-10-01" "aid" => "3282" "copyright" => "Asociación Española de Pediatría" "documento" => "simple-article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "crp" "cita" => "An Pediatr (Barc). 2022;97:288-9" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "Scientific Letter" "titulo" => "Gray platelet syndrome, more than just a bleeding disorder" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "288" "paginaFinal" => "289" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Síndrome de plaquetas grises, algo más que un trastorno hemorrágico" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Alexandra Regueiro García, Sabela Fariña Nogueira, Susana Rujido Freire, Graciela Gómez Silva, Manuel Fernández Sanmartín" "autores" => array:5 [ 0 => array:2 [ "nombre" => "Alexandra" "apellidos" => "Regueiro García" ] 1 => array:2 [ "nombre" => "Sabela" "apellidos" => "Fariña Nogueira" ] 2 => array:2 [ "nombre" => "Susana" "apellidos" => "Rujido Freire" ] 3 => array:2 [ "nombre" => "Graciela" "apellidos" => "Gómez Silva" ] 4 => array:2 [ "nombre" => "Manuel" "apellidos" => "Fernández Sanmartín" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S1695403322001370" "doi" => "10.1016/j.anpedi.2022.04.014" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1695403322001370?idApp=UINPBA00005H" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2341287922001727?idApp=UINPBA00005H" "url" => "/23412879/0000009700000004/v2_202211110733/S2341287922001727/v2_202211110733/en/main.assets" ] "itemAnterior" => array:20 [ "pii" => "S2341287922001697" "issn" => "23412879" "doi" => "10.1016/j.anpede.2022.05.006" "estado" => "S300" "fechaPublicacion" => "2022-10-01" "aid" => "3290" "copyright" => "Asociación Española de Pediatría" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "crp" "cita" => "An Pediatr (Barc). 2022;97:284-6" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "Scientific Letter" "titulo" => "Analysis of pancreatic function in pediatric patients with COVID-19" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "284" "paginaFinal" => "286" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Análisis de la función pancreática en pacientes pediátricos con COVID-19" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 3916 "Ancho" => 1675 "Tamanyo" => 621953 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "Analysis of pancreatic function." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Miguel Ángel Molina Gutiérrez, María José Alcázar Villar, José Antonio Ruíz Domínguez, Belén Sagastizábal Cardelús, Beatríz García Cuartero" "autores" => array:6 [ 0 => array:2 [ "nombre" => "Miguel Ángel" "apellidos" => "Molina Gutiérrez" ] 1 => array:2 [ "nombre" => "María José" "apellidos" => "Alcázar Villar" ] 2 => array:2 [ "nombre" => "José Antonio" "apellidos" => "Ruíz Domínguez" ] 3 => array:2 [ "nombre" => "Belén" "apellidos" => "Sagastizábal Cardelús" ] 4 => array:2 [ "nombre" => "Beatríz" "apellidos" => "García Cuartero" ] 5 => array:1 [ "colaborador" => "on behalf of the Research Group on Urgent Paediatric Endocrinological Diseases" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S169540332200145X" "doi" => "10.1016/j.anpedi.2022.05.005" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S169540332200145X?idApp=UINPBA00005H" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2341287922001697?idApp=UINPBA00005H" "url" => "/23412879/0000009700000004/v2_202211110733/S2341287922001697/v2_202211110733/en/main.assets" ] "en" => array:17 [ "idiomaDefecto" => true "cabecera" => "Scientific Letter" "titulo" => "Treatment for acquired aplasia and refractory cytopenia. Review of a historical cohort" "tieneTextoCompleto" => true "saludo" => "Dear Editor:" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "286" "paginaFinal" => "288" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Jesús González de Pablo, Cristina Jiménez Cobo, Daniel Azorín Cuadrillero, Marta González-Vicent, Julián Sevilla" "autores" => array:5 [ 0 => array:2 [ "nombre" => "Jesús" "apellidos" => "González de Pablo" ] 1 => array:2 [ "nombre" => "Cristina" "apellidos" => "Jiménez Cobo" ] 2 => array:2 [ "nombre" => "Daniel" "apellidos" => "Azorín Cuadrillero" ] 3 => array:2 [ "nombre" => "Marta" "apellidos" => "González-Vicent" ] 4 => array:4 [ "nombre" => "Julián" "apellidos" => "Sevilla" "email" => array:1 [ 0 => "julian.sevilla@salud.madrid.org" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "*" "identificador" => "cor0005" ] ] ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Hospital Infantil Universitario Niño Jesús, Madrid, Spain" "identificador" => "aff0005" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Tratamiento de la aplasia adquirida y la citopenia refractaria. Revisión de una cohorte histórica" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1234 "Ancho" => 3006 "Tamanyo" => 160218 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "(A) Disease-free survival in the cohort following first-line treatment. (B) Overall survival after immunosuppressive therapy depending on the time elapsed from diagnosis to treatment." ] ] ] "textoCompleto" => "Recently, we reviewed the experience in our hospital in the management of acquired aplastic anaemia (AAA) and refractory cytopenia in childhood (RCC), in accordance with the recommendations and studies associated with the a European Society for Blood and Marrow Transplantation (EBMT).<a class="elsevierStyleCrossRefs" href="#bib0005">1,2</a> Acquired aplastic anaemia is the most common form of acquired bone marrow failure, with an estimated incidence of 1.5 cases per 2 million individuals per year in Europe.<a class="elsevierStyleCrossRef" href="#bib0005">1</a> Refractory cytopenia in childhood is the most common myelodysplastic syndrome in children. It is recommended that these patients receive the same treatment established for AAA, based on haematopoietic stem cell transplantation (HSCT) or immunosuppressive therapy (IST).<a class="elsevierStyleCrossRef" href="#bib0015">3</a> The aim of our study was to retrospectively assess the response rate, event-free survival and overall survival of patients with AAA and RCC that underwent HCST or IST.The study included 48 patients with a diagnosis of AAA or RCC managed at the Hospital Infantil Universitario Niño Jesús between 2001 and 2020. Two patients (4.08%) did not received treatment, one due to spontaneous recovery and the other due to paroxysmal nocturnal haemoglobinuria (PNH) clone expansion, which did not require treatment until the patient was transferred to another centre. We defined complete remission (CR) as a neutrophil count of 1.5 × 109/L or greater, a platelet count of 150 × 109/L or greater and a haemoglobin concentration of 10.5–13 g/dL.<a class="elsevierStyleCrossRef" href="#bib0005">1</a> We defined partial remission (PR) as the achievement of transfusion independence. The events taken into account in the analysis of event-free survival (EFS) were relapse and death. We used Kaplan-Meier survival analysis to generate cumulative incidence curves and compared the results by means of the log-rank test.We found an overall survival (OS) in the case series of 90.6%. The 9 patients (18.75%) that underwent HLA-matched related donor HSCT achieved CR without requiring further treatment. In the remaining 37 patients (77.08%), IST was used for first-line treatment with a response rate of 73% (18/37 CR and 9/37 PR). Comparing the outcomes of initial treatment, we found that the OS with HSCT was 100% compared to 85% with IST as first-line treatment (P = .321). The comparison of HSCT versus IST for first-line treatment did find a significant difference when it came to EFS: 100% with HSCT as first-line treatment compared to 47.1% with IST (P = .038) (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>A). The response rate in the 13 patients that required additional courses of IST was 61.5% (4/13 CR and 4/13 PR). The EFS with HSCT as second-line treatment was 62.5% compared to 50% with IST as second-line treatment. Of the 5 patients that did not respond to the second course of IST, 3 received transplants from alternative donors, which achieved an increase of OS with IST as second-line treatment to 83.9%. The median time elapsed from diagnosis and initiation of IST as first-line treatment was 23 days (0–180). The analysis of the association of different factors with OS in these patients showed a negative correlation of the time elapsed to initiation of the first course of IST with OS. A delay in treatment initiation of more than 30 days from diagnosis had a significant impact on treatment outcomes (96.3% vs 48.1%; P = .005) (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>B).<elsevierMultimedia ident="fig0005"></elsevierMultimedia>The results of our study show that the OS achieved with first-line treatment can be considered optimal, with poorer outcomes in terms of EFS. Our findings were consistent with those of previous case series.<a class="elsevierStyleCrossRefs" href="#bib0020">4–6</a> One third of the patients in our series did not require allogeneic transplantation and could be rescued with IST in the absence of an HLA-identical related donor. We also found that HSCT as second-line treatment was a good salvage therapy option after 1 course of IST, with a survival greater than 60%. We ought to highlight that the outcomes found in different groups and lines of treatment should not be interpreted with the aim of improving treatment selection, as the retrospective design of this case series only allows the description of what happened with each line of treatment as opposed to an applicable comparison (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>).<elsevierMultimedia ident="tbl0005"></elsevierMultimedia>At present, the appropriateness of using HSCT for first-line treatment of these patients independently of the type of donor available is being investigated due to the excellent outcomes observed in patients managed with this approach, as was the case in our series with treatment with HLA-matched related donor HSCT. However, we think it is important to take into account that as many as a third of the patients may achieve a cure with IST alone. Although it may be even more important to underscore that, if IST is used as first-line treatment, it should be initiated within 30 days of diagnosis to avoid a negative impact on its outcomes." "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2022-01-13" "fechaAceptado" => "2022-04-26" "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "Previous presentations: This study was presented in the LXIII National Congress of the Sociedad Española de Hematología y Hemoterapia and the XXXVII National Congress of the Sociedad Española de Trombosis y Hemostasia, held in 2021 in Pamplona, Spain." ] ] "multimedia" => array:2 [ 0 => array:8 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1234 "Ancho" => 3006 "Tamanyo" => 160218 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "(A) Disease-free survival in the cohort following first-line treatment. (B) Overall survival after immunosuppressive therapy depending on the time elapsed from diagnosis to treatment." ] ] 1 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0010" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "Ranges given as Q1-Q3.ATGAM, equine anti-thymocyte immune globulin; CMV, human cytomegalovirus; CsA, cyclosporine A; GvHD, graft versus host disease; HLA, human leukocyte antigen; HSCT, haematopoietic stem cell transplantation; IST, immunosuppressive therapy; PNH, paroxysmal nocturnal haemoglobinuria; RCC, refractory cytopenia in childhood." "tablatextoimagen" => array:1 [ 0 => array:1 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">N \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">48 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Age at diagnosis (years) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">11 (8−14) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Median duration of follow-up (months) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">36 (13−79) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Sex \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Male (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">33 (69%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Female (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">15 (31%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Diagnosis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Acquired aplasia (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">33 (68.8%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">RCC (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">15 (31.3%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">IST as first-line, total (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">37 (77.08%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">ATGAM (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">21 (43.75%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Thymoglobulin (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">16 (33.33%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Severe neutropenia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">21 (56.7%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Transfusion dependence \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">24 (68.8%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Spontaneous remission \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 (2.08%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Progression to PNH \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 (2.08%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">HSCT, total (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">20 (41.6%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">HSCT as first-line (HLA-identical related donor) (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">9 (18.75%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">HSCT > first line (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">11 (22.91%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Conditioning \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Myeloablative \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5 (25%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Reduced toxicity \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">15 (75%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Outcome of patients that underwent HSCT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">No GvHD \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">14 (70%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Acute GvHD \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5 (25%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Chronic GvHD \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 (5%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">In complete remission (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">16 (80%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Deceased (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4 (20%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Outcomes of patients treated with IST \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">In complete remission (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">17 (35.4%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">In treatment with CsA (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">7 (18.9%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Posterior HSCT (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">11 (29.7%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Death during IST (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 (2.7%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Lost to follow-up (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 (2.7%) \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] ] ] ] "descripcion" => array:1 [ "en" => "Characteristics of the total cohort of patients and their treatment." ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:6 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Guía para el diagnóstico y el tratamiento de las insuficiencias medulares" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:7 [ 0 => "C. Solano Vercet" 1 => "L. Vázquez López" 2 => "J. Sanz Caballer" 3 => "I. García Cadenas" 4 => "I. Sánchez-Ortega Sánchez" 5 => "O. Salamero García" 6 => "GrupoEspa˜nol de Trasplante Hematopoyético y Terapia Celular (GETH)" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:3 [ "fecha" => "2019" "editorial" => "SEHH, SEHOP" "editorialLocalizacion" => "Madrid" ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy-The European Group for Blood and Marrow Transplantation experience" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Bacigalupo" 1 => "R. Brand" 2 => "R. Oneto" 3 => "B. Bruno" 4 => "G. Socié" 5 => "J. Passweg" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/s0037-1963(00)90031-3" "Revista" => array:8 [ "tituloSerie" => "Semin Hematol." "fecha" => "2000" "volumen" => "37" "numero" => "1" "paginaInicial" => "69" "paginaFinal" => "80" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10676912" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0010782411002241" "estado" => "S300" "issn" => "00107824" ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "How I treat myelodysplastic syndromes of childhood" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "F. Locatelli" 1 => "B. Strahm" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1182/blood-2017-09-765214" "Revista" => array:7 [ "tituloSerie" => "Blood." "fecha" => "2018" "volumen" => "131" "numero" => "13" "paginaInicial" => "1406" "paginaFinal" => "1414" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29438960" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Outcome of aplastic anemia in adolescence: a survey of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C. Dufour" 1 => "M. Pillon" 2 => "J. Passweg" 3 => "G. Socié" 4 => "A. Bacigalupo" 5 => "G. Franceschetto" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3324/haematol.2014.106096" "Revista" => array:7 [ "tituloSerie" => "Haematologica." "fecha" => "2014" "volumen" => "99" "numero" => "10" "paginaInicial" => "1574" "paginaFinal" => "1581" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25085353" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A study assessing the feasibility of randomization of pediatric and young adult patients between matched unrelated donor bone marrow transplantation and immune-suppressive therapy for newly diagnosed severe aplastic anemia: a joint pilot trial of the North American Pediatric Aplastic Anemia Consortium and the Pediatric Transplantation and Cellular Therapy Consortium" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M.A. Pulsipher" 1 => "L.E. Lehmann" 2 => "A.A. Bertuch" 3 => "G. Sasa" 4 => "T. Olson" 5 => "T. Nakano" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "Pediatr Blood Cancer." "fecha" => "2020" "volumen" => "67" "numero" => "10" ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pediatric aplastic anemia and refractory cytopenia: a retrospective analysis assessing outcomes and histomorphologic predictors" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C.M. Forester" 1 => "S.E. Sartain" 2 => "D. Guo" 3 => "M.H. Harris" 4 => "O.K. Weinberg" 5 => "M.D. Fleming" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/ajh.23937" "Revista" => array:7 [ "tituloSerie" => "Am J Hematol." "fecha" => "2015" "volumen" => "90" "numero" => "4" "paginaInicial" => "320" "paginaFinal" => "326" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25580823" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/23412879/0000009700000004/v2_202211110733/S2341287922001843/v2_202211110733/en/main.assets" "Apartado" => array:4 [ "identificador" => "38181" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Scientific letters" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/23412879/0000009700000004/v2_202211110733/S2341287922001843/v2_202211110733/en/main.pdf?idApp=UINPBA00005H&text.app=https://www.analesdepediatria.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2341287922001843?idApp=UINPBA00005H"]

Statistics

Scientific Letter

Treatment for acquired aplasia and refractory cytopenia. Review of a historical cohort

Tratamiento de la aplasia adquirida y la citopenia refractaria. Revisión de una cohorte histórica

Jesús González de Pablo, Cristina Jiménez Cobo, Daniel Azorín Cuadrillero, Marta González-Vicent, Julián Sevilla

Corresponding author

julian.sevilla@salud.madrid.org

Corresponding author.

Hospital Infantil Universitario Niño Jesús, Madrid, Spain

Read

3888

Times
was read the article

2345

Total PDF

1543

Total HTML

Share statistics

 array:24 [
  "pii" => "S2341287922001843"
  "issn" => "23412879"
  "doi" => "10.1016/j.anpede.2022.08.006"
  "estado" => "S300"
  "fechaPublicacion" => "2022-10-01"
  "aid" => "3284"
  "copyrightAnyo" => "2022"
  "documento" => "article"
  "crossmark" => 1
  "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
  "subdocumento" => "crp"
  "cita" => "An Pediatr &#40;Barc&#41;. 2022;97:286-8"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:1 [
    "total" => 0
  ]
  "Traduccion" => array:1 [
    "es" => array:20 [
      "pii" => "S1695403322001394"
      "issn" => "16954033"
      "doi" => "10.1016/j.anpedi.2022.04.016"
      "estado" => "S300"
      "fechaPublicacion" => "2022-10-01"
      "aid" => "3284"
      "copyright" => "Asociaci&#243;n Espa&#241;ola de Pediatr&#237;a"
      "documento" => "simple-article"
      "crossmark" => 1
      "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
      "subdocumento" => "crp"
      "cita" => "An Pediatr &#40;Barc&#41;. 2022;97:286-8"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:1 [
        "total" => 0
      ]
      "es" => array:11 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Carta cient&#237;fica</span>"
        "titulo" => "Tratamiento de la aplasia adquirida y la citopenia refractaria&#46; Revisi&#243;n de una cohorte hist&#243;rica"
        "tienePdf" => "es"
        "tieneTextoCompleto" => "es"
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "286"
            "paginaFinal" => "288"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Treatment for acquired aplasia and refractory cytopenia&#46; Review of a historical cohort"
          ]
        ]
        "contieneTextoCompleto" => array:1 [
          "es" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 0
          "multimedia" => array:7 [
            "identificador" => "fig0005"
            "etiqueta" => "Figura 1"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => true
            "mostrarDisplay" => false
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "gr1.jpeg"
                "Alto" => 1224
                "Ancho" => 2917
                "Tamanyo" => 147510
              ]
            ]
            "descripcion" => array:1 [
              "es" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">A&#46; Supervivencia libre de enfermedad de la cohorte tras primer tratamiento&#46; B&#46; Supervivencia global tras tratamiento inmunosupresor dependiendo del periodo entre diagn&#243;stico y tratamiento&#46;</p>"
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "Jes&#250;s Gonz&#225;lez de Pablo, Cristina Jim&#233;nez Cobo, Daniel Azor&#237;n Cuadrillero, Marta Gonz&#225;lez-Vicent, Juli&#225;n Sevilla"
            "autores" => array:5 [
              0 => array:2 [
                "nombre" => "Jes&#250;s"
                "apellidos" => "Gonz&#225;lez de Pablo"
              ]
              1 => array:2 [
                "nombre" => "Cristina"
                "apellidos" => "Jim&#233;nez Cobo"
              ]
              2 => array:2 [
                "nombre" => "Daniel"
                "apellidos" => "Azor&#237;n Cuadrillero"
              ]
              3 => array:2 [
                "nombre" => "Marta"
                "apellidos" => "Gonz&#225;lez-Vicent"
              ]
              4 => array:2 [
                "nombre" => "Juli&#225;n"
                "apellidos" => "Sevilla"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "S2341287922001843"
          "doi" => "10.1016/j.anpede.2022.08.006"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2341287922001843?idApp=UINPBA00005H"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1695403322001394?idApp=UINPBA00005H"
      "url" => "/16954033/0000009700000004/v1_202210061345/S1695403322001394/v1_202210061345/es/main.assets"
    ]
  ]
  "itemSiguiente" => array:20 [
    "pii" => "S2341287922001727"
    "issn" => "23412879"
    "doi" => "10.1016/j.anpede.2022.04.012"
    "estado" => "S300"
    "fechaPublicacion" => "2022-10-01"
    "aid" => "3282"
    "copyright" => "Asociaci&#243;n Espa&#241;ola de Pediatr&#237;a"
    "documento" => "simple-article"
    "crossmark" => 1
    "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
    "subdocumento" => "crp"
    "cita" => "An Pediatr &#40;Barc&#41;. 2022;97:288-9"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:10 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Scientific Letter</span>"
      "titulo" => "Gray platelet syndrome&#44; more than just a bleeding disorder"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "288"
          "paginaFinal" => "289"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "S&#237;ndrome de plaquetas grises&#44; algo m&#225;s que un trastorno hemorr&#225;gico"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Alexandra Regueiro Garc&#237;a, Sabela Fari&#241;a Nogueira, Susana Rujido Freire, Graciela G&#243;mez Silva, Manuel Fern&#225;ndez Sanmart&#237;n"
          "autores" => array:5 [
            0 => array:2 [
              "nombre" => "Alexandra"
              "apellidos" => "Regueiro Garc&#237;a"
            ]
            1 => array:2 [
              "nombre" => "Sabela"
              "apellidos" => "Fari&#241;a Nogueira"
            ]
            2 => array:2 [
              "nombre" => "Susana"
              "apellidos" => "Rujido Freire"
            ]
            3 => array:2 [
              "nombre" => "Graciela"
              "apellidos" => "G&#243;mez Silva"
            ]
            4 => array:2 [
              "nombre" => "Manuel"
              "apellidos" => "Fern&#225;ndez Sanmart&#237;n"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S1695403322001370"
        "doi" => "10.1016/j.anpedi.2022.04.014"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1695403322001370?idApp=UINPBA00005H"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2341287922001727?idApp=UINPBA00005H"
    "url" => "/23412879/0000009700000004/v2_202211110733/S2341287922001727/v2_202211110733/en/main.assets"
  ]
  "itemAnterior" => array:20 [
    "pii" => "S2341287922001697"
    "issn" => "23412879"
    "doi" => "10.1016/j.anpede.2022.05.006"
    "estado" => "S300"
    "fechaPublicacion" => "2022-10-01"
    "aid" => "3290"
    "copyright" => "Asociaci&#243;n Espa&#241;ola de Pediatr&#237;a"
    "documento" => "article"
    "crossmark" => 1
    "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
    "subdocumento" => "crp"
    "cita" => "An Pediatr &#40;Barc&#41;. 2022;97:284-6"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:11 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Scientific Letter</span>"
      "titulo" => "Analysis of pancreatic function in pediatric patients with COVID-19"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "284"
          "paginaFinal" => "286"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "An&#225;lisis de la funci&#243;n pancre&#225;tica en pacientes pedi&#225;tricos con COVID-19"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:8 [
          "identificador" => "fig0005"
          "etiqueta" => "Figure 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 3916
              "Ancho" => 1675
              "Tamanyo" => 621953
            ]
          ]
          "detalles" => array:1 [
            0 => array:3 [
              "identificador" => "at0005"
              "detalle" => "Figure "
              "rol" => "short"
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Analysis of pancreatic function&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Miguel &#193;ngel Molina Guti&#233;rrez, Mar&#237;a Jos&#233; Alc&#225;zar Villar, Jos&#233; Antonio Ru&#237;z Dom&#237;nguez, Bel&#233;n Sagastiz&#225;bal Cardel&#250;s, Beatr&#237;z Garc&#237;a Cuartero"
          "autores" => array:6 [
            0 => array:2 [
              "nombre" => "Miguel &#193;ngel"
              "apellidos" => "Molina Guti&#233;rrez"
            ]
            1 => array:2 [
              "nombre" => "Mar&#237;a Jos&#233;"
              "apellidos" => "Alc&#225;zar Villar"
            ]
            2 => array:2 [
              "nombre" => "Jos&#233; Antonio"
              "apellidos" => "Ru&#237;z Dom&#237;nguez"
            ]
            3 => array:2 [
              "nombre" => "Bel&#233;n"
              "apellidos" => "Sagastiz&#225;bal Cardel&#250;s"
            ]
            4 => array:2 [
              "nombre" => "Beatr&#237;z"
              "apellidos" => "Garc&#237;a Cuartero"
            ]
            5 => array:1 [
              "colaborador" => "on behalf of the Research Group on Urgent Paediatric Endocrinological Diseases"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S169540332200145X"
        "doi" => "10.1016/j.anpedi.2022.05.005"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S169540332200145X?idApp=UINPBA00005H"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2341287922001697?idApp=UINPBA00005H"
    "url" => "/23412879/0000009700000004/v2_202211110733/S2341287922001697/v2_202211110733/en/main.assets"
  ]
  "en" => array:17 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Scientific Letter</span>"
    "titulo" => "Treatment for acquired aplasia and refractory cytopenia&#46; Review of a historical cohort"
    "tieneTextoCompleto" => true
    "saludo" => "Dear Editor&#58;"
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "286"
        "paginaFinal" => "288"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "Jes&#250;s Gonz&#225;lez de Pablo, Cristina Jim&#233;nez Cobo, Daniel Azor&#237;n Cuadrillero, Marta Gonz&#225;lez-Vicent, Juli&#225;n Sevilla"
        "autores" => array:5 [
          0 => array:2 [
            "nombre" => "Jes&#250;s"
            "apellidos" => "Gonz&#225;lez de Pablo"
          ]
          1 => array:2 [
            "nombre" => "Cristina"
            "apellidos" => "Jim&#233;nez Cobo"
          ]
          2 => array:2 [
            "nombre" => "Daniel"
            "apellidos" => "Azor&#237;n Cuadrillero"
          ]
          3 => array:2 [
            "nombre" => "Marta"
            "apellidos" => "Gonz&#225;lez-Vicent"
          ]
          4 => array:4 [
            "nombre" => "Juli&#225;n"
            "apellidos" => "Sevilla"
            "email" => array:1 [
              0 => "julian.sevilla@salud.madrid.org"
            ]
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:1 [
          0 => array:2 [
            "entidad" => "Hospital Infantil Universitario Ni&#241;o Jes&#250;s&#44; Madrid&#44; Spain"
            "identificador" => "aff0005"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Corresponding author&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Tratamiento de la aplasia adquirida y la citopenia refractaria&#46; Revisi&#243;n de una cohorte hist&#243;rica"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:8 [
        "identificador" => "fig0005"
        "etiqueta" => "Figure 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 1234
            "Ancho" => 3006
            "Tamanyo" => 160218
          ]
        ]
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at0005"
            "detalle" => "Figure "
            "rol" => "short"
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">&#40;A&#41; Disease-free survival in the cohort following first-line treatment&#46; &#40;B&#41; Overall survival after immunosuppressive therapy depending on the time elapsed from diagnosis to treatment&#46;</p>"
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Recently&#44; we reviewed the experience in our hospital in the management of acquired aplastic anaemia &#40;AAA&#41; and refractory cytopenia in childhood &#40;RCC&#41;&#44; in accordance with the recommendations and studies associated with the a European Society for Blood and Marrow Transplantation &#40;EBMT&#41;&#46;<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1&#44;2</span></a> Acquired aplastic anaemia is the most common form of acquired bone marrow failure&#44; with an estimated incidence of 1&#46;5 cases per 2 million individuals per year in Europe&#46;<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> Refractory cytopenia in childhood is the most common myelodysplastic syndrome in children&#46; It is recommended that these patients receive the same treatment established for AAA&#44; based on haematopoietic stem cell transplantation &#40;HSCT&#41; or immunosuppressive therapy &#40;IST&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a> The aim of our study was to retrospectively assess the response rate&#44; event-free survival and overall survival of patients with AAA and RCC that underwent HCST or IST&#46;</p><p id="par0010" class="elsevierStylePara elsevierViewall">The study included 48 patients with a diagnosis of AAA or RCC managed at the Hospital Infantil Universitario Ni&#241;o Jes&#250;s between 2001 and 2020&#46; Two patients &#40;4&#46;08&#37;&#41; did not received treatment&#44; one due to spontaneous recovery and the other due to paroxysmal nocturnal haemoglobinuria &#40;PNH&#41; clone expansion&#44; which did not require treatment until the patient was transferred to another centre&#46; We defined complete remission &#40;CR&#41; as a neutrophil count of 1&#46;5 &#215; 10<span class="elsevierStyleSup">9</span>&#47;L or greater&#44; a platelet count of 150 &#215; 10<span class="elsevierStyleSup">9</span>&#47;L or greater and a haemoglobin concentration of 10&#46;5&#8211;13 g&#47;dL&#46;<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> We defined partial remission &#40;PR&#41; as the achievement of transfusion independence&#46; The events taken into account in the analysis of event-free survival &#40;EFS&#41; were relapse and death&#46; We used Kaplan-Meier survival analysis to generate cumulative incidence curves and compared the results by means of the log-rank test&#46;</p><p id="par0015" class="elsevierStylePara elsevierViewall">We found an overall survival &#40;OS&#41; in the case series of 90&#46;6&#37;&#46; The 9 patients &#40;18&#46;75&#37;&#41; that underwent HLA-matched related donor HSCT achieved CR without requiring further treatment&#46; In the remaining 37 patients &#40;77&#46;08&#37;&#41;&#44; IST was used for first-line treatment with a response rate of 73&#37; &#40;18&#47;37 CR and 9&#47;37 PR&#41;&#46; Comparing the outcomes of initial treatment&#44; we found that the OS with HSCT was 100&#37; compared to 85&#37; with IST as first-line treatment &#40;<span class="elsevierStyleItalic">P</span> &#61; &#46;321&#41;&#46; The comparison of HSCT versus IST for first-line treatment did find a significant difference when it came to EFS&#58; 100&#37; with HSCT as first-line treatment compared to 47&#46;1&#37; with IST &#40;<span class="elsevierStyleItalic">P</span> &#61; &#46;038&#41; &#40;<a class="elsevierStyleCrossRef" href="#fig0005">Fig&#46; 1</a>A&#41;&#46; The response rate in the 13 patients that required additional courses of IST was 61&#46;5&#37; &#40;4&#47;13 CR and 4&#47;13 PR&#41;&#46; The EFS with HSCT as second-line treatment was 62&#46;5&#37; compared to 50&#37; with IST as second-line treatment&#46; Of the 5 patients that did not respond to the second course of IST&#44; 3 received transplants from alternative donors&#44; which achieved an increase of OS with IST as second-line treatment to 83&#46;9&#37;&#46; The median time elapsed from diagnosis and initiation of IST as first-line treatment was 23 days &#40;0&#8211;180&#41;&#46; The analysis of the association of different factors with OS in these patients showed a negative correlation of the time elapsed to initiation of the first course of IST with OS&#46; A delay in treatment initiation of more than 30 days from diagnosis had a significant impact on treatment outcomes &#40;96&#46;3&#37; vs 48&#46;1&#37;&#59; <span class="elsevierStyleItalic">P</span> &#61; &#46;005&#41; &#40;<a class="elsevierStyleCrossRef" href="#fig0005">Fig&#46; 1</a>B&#41;&#46;</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0020" class="elsevierStylePara elsevierViewall">The results of our study show that the OS achieved with first-line treatment can be considered optimal&#44; with poorer outcomes in terms of EFS&#46; Our findings were consistent with those of previous case series&#46;<a class="elsevierStyleCrossRefs" href="#bib0020"><span class="elsevierStyleSup">4&#8211;6</span></a> One third of the patients in our series did not require allogeneic transplantation and could be rescued with IST in the absence of an HLA-identical related donor&#46; We also found that HSCT as second-line treatment was a good salvage therapy option after 1 course of IST&#44; with a survival greater than 60&#37;&#46; We ought to highlight that the outcomes found in different groups and lines of treatment should not be interpreted with the aim of improving treatment selection&#44; as the retrospective design of this case series only allows the description of what happened with each line of treatment as opposed to an applicable comparison &#40;<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#41;&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0025" class="elsevierStylePara elsevierViewall">At present&#44; the appropriateness of using HSCT for first-line treatment of these patients independently of the type of donor available is being investigated due to the excellent outcomes observed in patients managed with this approach&#44; as was the case in our series with treatment with HLA-matched related donor HSCT&#46; However&#44; we think it is important to take into account that as many as a third of the patients may achieve a cure with IST alone&#46; Although it may be even more important to underscore that&#44; if IST is used as first-line treatment&#44; it should be initiated within 30 days of diagnosis to avoid a negative impact on its outcomes&#46;</p></span>"
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "fechaRecibido" => "2022-01-13"
    "fechaAceptado" => "2022-04-26"
    "NotaPie" => array:1 [
      0 => array:2 [
        "etiqueta" => "&#9734;"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Previous presentations&#58; This study was presented in the LXIII National Congress of the Sociedad Espa&#241;ola de Hematolog&#237;a y Hemoterapia and the <span class="elsevierStyleSmallCaps">XXXVII</span> National Congress of the Sociedad Espa&#241;ola de Trombosis y Hemostasia&#44; held in 2021 in Pamplona&#44; Spain&#46;</p>"
      ]
    ]
    "multimedia" => array:2 [
      0 => array:8 [
        "identificador" => "fig0005"
        "etiqueta" => "Figure 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 1234
            "Ancho" => 3006
            "Tamanyo" => 160218
          ]
        ]
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at0005"
            "detalle" => "Figure "
            "rol" => "short"
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">&#40;A&#41; Disease-free survival in the cohort following first-line treatment&#46; &#40;B&#41; Overall survival after immunosuppressive therapy depending on the time elapsed from diagnosis to treatment&#46;</p>"
        ]
      ]
      1 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Table 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at0010"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Ranges given as Q1-Q3&#46;</p><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">ATGAM&#44; equine anti-thymocyte immune globulin&#59; CMV&#44; human cytomegalovirus&#59; CsA&#44; cyclosporine A&#59; GvHD&#44; graft versus host disease&#59; HLA&#44; human leukocyte antigen&#59; HSCT&#44; haematopoietic stem cell transplantation&#59; IST&#44; immunosuppressive therapy&#59; PNH&#44; paroxysmal nocturnal haemoglobinuria&#59; RCC&#44; refractory cytopenia in childhood&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:1 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">N&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">48&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Age at diagnosis &#40;years&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11 &#40;8&#8722;14&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Median duration of follow-up &#40;months&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">36 &#40;13&#8722;79&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Sex</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Male &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">33 &#40;69&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Female &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">15 &#40;31&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Diagnosis</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Acquired aplasia &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">33 &#40;68&#46;8&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>RCC &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">15 &#40;31&#46;3&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">IST as first-line&#44; total &#40;&#37;&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">37 &#40;77&#46;08&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>ATGAM &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">21 &#40;43&#46;75&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Thymoglobulin &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">16 &#40;33&#46;33&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Severe neutropenia&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">21 &#40;56&#46;7&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Transfusion dependence&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">24 &#40;68&#46;8&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Spontaneous remission</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1 &#40;2&#46;08&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Progression to PNH</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1 &#40;2&#46;08&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">HSCT&#44; total &#40;&#37;&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">20 &#40;41&#46;6&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>HSCT as first-line &#40;HLA-identical related donor&#41; &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">9 &#40;18&#46;75&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>HSCT &#62; first line &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11 &#40;22&#46;91&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Conditioning</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Myeloablative&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5 &#40;25&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Reduced toxicity&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">15 &#40;75&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Outcome of patients that underwent HSCT</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>No GvHD&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">14 &#40;70&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Acute GvHD&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5 &#40;25&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Chronic GvHD&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1 &#40;5&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>In complete remission &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">16 &#40;80&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Deceased &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4 &#40;20&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Outcomes of patients treated with IST</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>In complete remission &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">17 &#40;35&#46;4&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>In treatment with CsA &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7 &#40;18&#46;9&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Posterior HSCT &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11 &#40;29&#46;7&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Death during IST &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1 &#40;2&#46;7&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Lost to follow-up &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1 &#40;2&#46;7&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Characteristics of the total cohort of patients and their treatment&#46;</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0005"
          "bibliografiaReferencia" => array:6 [
            0 => array:3 [
              "identificador" => "bib0005"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Gu&#237;a para el diagn&#243;stico y el tratamiento de las insuficiencias medulares"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:7 [
                            0 => "C&#46; Solano Vercet"
                            1 => "L&#46; V&#225;zquez L&#243;pez"
                            2 => "J&#46; Sanz Caballer"
                            3 => "I&#46; Garc&#237;a Cadenas"
                            4 => "I&#46; S&#225;nchez-Ortega S&#225;nchez"
                            5 => "O&#46; Salamero Garc&#237;a"
                            6 => "GrupoEspa&#732;nol de Trasplante Hematopoy&#233;tico y Terapia Celular &#40;GETH&#41;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Libro" => array:3 [
                        "fecha" => "2019"
                        "editorial" => "SEHH&#44; SEHOP"
                        "editorialLocalizacion" => "Madrid"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0010"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment of acquired severe aplastic anemia&#58; bone marrow transplantation compared with immunosuppressive therapy-The European Group for Blood and Marrow Transplantation experience"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "A&#46; Bacigalupo"
                            1 => "R&#46; Brand"
                            2 => "R&#46; Oneto"
                            3 => "B&#46; Bruno"
                            4 => "G&#46; Soci&#233;"
                            5 => "J&#46; Passweg"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/s0037-1963(00)90031-3"
                      "Revista" => array:8 [
                        "tituloSerie" => "Semin Hematol&#46;"
                        "fecha" => "2000"
                        "volumen" => "37"
                        "numero" => "1"
                        "paginaInicial" => "69"
                        "paginaFinal" => "80"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10676912"
                            "web" => "Medline"
                          ]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S0010782411002241"
                          "estado" => "S300"
                          "issn" => "00107824"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0015"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "How I treat myelodysplastic syndromes of childhood"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "F&#46; Locatelli"
                            1 => "B&#46; Strahm"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1182/blood-2017-09-765214"
                      "Revista" => array:7 [
                        "tituloSerie" => "Blood&#46;"
                        "fecha" => "2018"
                        "volumen" => "131"
                        "numero" => "13"
                        "paginaInicial" => "1406"
                        "paginaFinal" => "1414"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29438960"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0020"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Outcome of aplastic anemia in adolescence&#58; a survey of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "C&#46; Dufour"
                            1 => "M&#46; Pillon"
                            2 => "J&#46; Passweg"
                            3 => "G&#46; Soci&#233;"
                            4 => "A&#46; Bacigalupo"
                            5 => "G&#46; Franceschetto"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3324/haematol.2014.106096"
                      "Revista" => array:7 [
                        "tituloSerie" => "Haematologica&#46;"
                        "fecha" => "2014"
                        "volumen" => "99"
                        "numero" => "10"
                        "paginaInicial" => "1574"
                        "paginaFinal" => "1581"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25085353"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0025"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A study assessing the feasibility of randomization of pediatric and young adult patients between matched unrelated donor bone marrow transplantation and immune-suppressive therapy for newly diagnosed severe aplastic anemia&#58; a joint pilot trial of the North American Pediatric Aplastic Anemia Consortium and the Pediatric Transplantation and Cellular Therapy Consortium"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46;A&#46; Pulsipher"
                            1 => "L&#46;E&#46; Lehmann"
                            2 => "A&#46;A&#46; Bertuch"
                            3 => "G&#46; Sasa"
                            4 => "T&#46; Olson"
                            5 => "T&#46; Nakano"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:4 [
                        "tituloSerie" => "Pediatr Blood Cancer&#46;"
                        "fecha" => "2020"
                        "volumen" => "67"
                        "numero" => "10"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0030"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Pediatric aplastic anemia and refractory cytopenia&#58; a retrospective analysis assessing outcomes and histomorphologic predictors"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "C&#46;M&#46; Forester"
                            1 => "S&#46;E&#46; Sartain"
                            2 => "D&#46; Guo"
                            3 => "M&#46;H&#46; Harris"
                            4 => "O&#46;K&#46; Weinberg"
                            5 => "M&#46;D&#46; Fleming"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/ajh.23937"
                      "Revista" => array:7 [
                        "tituloSerie" => "Am J Hematol&#46;"
                        "fecha" => "2015"
                        "volumen" => "90"
                        "numero" => "4"
                        "paginaInicial" => "320"
                        "paginaFinal" => "326"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25580823"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/23412879/0000009700000004/v2_202211110733/S2341287922001843/v2_202211110733/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "38181"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Scientific letters"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/23412879/0000009700000004/v2_202211110733/S2341287922001843/v2_202211110733/en/main.pdf?idApp=UINPBA00005H&text.app=https://www.analesdepediatria.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2341287922001843?idApp=UINPBA00005H"
]

Article information

ISSN: 23412879
Original language: English

DOI:10.1016/j.anpede.2022.08.006

The statistics are updated each day

Year/Month	Html	Pdf	Total

2024 October	40	30	70
2024 September	61	49	110
2024 August	72	50	122
2024 July	49	35	84
2024 June	48	32	80
2024 May	50	42	92
2024 April	37	41	78
2024 March	37	1526	1563
2024 February	23	28	51
2024 January	47	21	68
2023 December	36	24	60
2023 November	63	31	94
2023 October	60	30	90
2023 September	69	28	97
2023 August	33	21	54
2023 July	75	22	97
2023 June	48	27	75
2023 May	85	33	118
2023 April	49	24	73
2023 March	86	21	107
2023 February	69	16	85
2023 January	58	17	75
2022 December	70	25	95
2022 November	70	24	94
2022 October	83	65	148
2022 September	77	54	131
2022 August	48	29	77

Show all

Indexed in:

Follow us:

Subscribe:

Statistics

Indexed in:

Follow us:

Subscribe:

Statistics

Subscribe to our newsletter